Juno Therapeutics and WuXi AppTec form JW Biotechnology
JW Biotechnology will focus on developing novel cell-based immunotherapies.
Juno Therapeutics and WuXi AppTec have started a new company in China, JW Biotechnology, according to an April 7, 2016 press announcement. JW Biotechnology will leverage Juno’s chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies and WuXi AppTec’s R&D and manufacturing platform to develop novel cell-based immunotherapies for patients with hematologic and solid organ cancers. James Li, MD, formerly a Kleiner Perkins partner and general manager of Amgen China, and a JW Biotechnology co-founder, has been appointed chief executive officer of JW Biotechnology.
Juno and WuXi AppTec have equal initial ownership in JW Biotechnology, which after meeting certain conditions will have access to licensing product candidates from Juno’s pipeline for development and commercialization in China. In exchange, Juno will receive an upfront payment in equity, milestone payments, and royalties on net sales.
Source: WuXi AppTec
EMA Recommends Imfinzi-Based Perioperative Regimen for Treating Resectable NSCLC
March 10th 2025The committee’s recommendation is based on results from a Phase III trial in which Imfinzi demonstrated a reduced risk of recurrence, progression, or death by 32% compared to neoadjuvant chemotherapy alone.
International Women’s Day 2025: A Promising Future for Gender Diversity in Pharma
March 8th 2025In an interview with BioPharm International®, Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
